{
  "DOI": "10.1186/s40246-022-00417-9",
  "ISSN": [
    "1479-7364"
  ],
  "URL": "http://dx.doi.org/10.1186/s40246-022-00417-9",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eBackground\u003c/jats:title\u003e\n                \u003cjats:p\u003ePharmacogenomic (PGx) testing has proved its utility and cost-effectiveness for some commonly prescribed cardiovascular disease (CVD) medications. In addition, PGx-guided dosing guidelines are now available for multiple CVD drugs, including clopidogrel, warfarin, and statins. The United Arab Emirates (UAE) population is diverse and multiethnic, with over 150 nationalities residing in the country. PGx-testing is not part of the standard of care in most global healthcare settings, including the UAE healthcare system. The first pharmacogenomic implementation clinical study in CVD has been approved recently, but multiple considerations needed evaluation before commencing. The current report appraises the PGx-clinical implementation procedure and the potential benefits of pursuing PGx-implementation initiatives in the UAE with global implications.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eMethods\u003c/jats:title\u003e\n                \u003cjats:p\u003ePatients prescribed one or more of the following drugs: clopidogrel, atorvastatin, rosuvastatin, and warfarin, were recruited. Genotyping selected genetic variants at genes interacting with the study drugs was performed by real-time PCR.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eResults\u003c/jats:title\u003e\n                \u003cjats:p\u003eFor the current pilot study, 160 patients were recruited. The genotypes and inferred haplotypes, diplotypes, and predicted phenotypes revealed that 11.9% of the participants were poor CYP2C19 metabolizers, 35% intermediate metabolizers, 28.1% normal metabolizers, and 25% rapid or ultrarapid metabolizers. Notably, 46.9% of our cohort should receive a recommendation to avoid using clopidogrel or consider an alternative medication. Regarding warfarin, only 20% of the participants exhibited reference alleles at \u003cjats:italic\u003eVKORC1\u003c/jats:italic\u003e-1639G \u0026gt; A, \u003cjats:italic\u003eCYP2C9\u003c/jats:italic\u003e*2, and \u003cjats:italic\u003eCYP2C9\u003c/jats:italic\u003e*3, leaving 80% with alternative genotypes at any of the two genes that can be integrated into the warfarin dosing algorithms and can be used whenever the patient receives a warfarin prescription. For statins, 31.5% of patients carried at least one allele at the genotyped \u003cjats:italic\u003eSLCO1B1\u003c/jats:italic\u003e variant (rs4149056), increasing their risk of developing myopathy. 96% of our cohort received at least one PGx-generated clinical recommendation for the studied drugs.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eConclusion\u003c/jats:title\u003e\n                \u003cjats:p\u003eThe current pilot analysis verified the feasibility of PGx-testing and the unforeseen high frequencies of patients currently treated with suboptimal drug regimens, which may potentially benefit from PGx testing.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e",
  "alternative-id": [
    "417"
  ],
  "article-number": "42",
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "10 August 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "16 September 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "25 September 2022"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Ethics approval and consent to participate",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "Consents were collected from all included subjects. This study was conducted in compliance with the Declaration of Helsinki and following the “Abu Dhabi Health Research and Technology Ethical Committee” approval (Ref. DOH/CVDC/2020/1187)."
    },
    {
      "group": {
        "label": "Consent for publication",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "Not applicable."
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 4,
      "value": "The authors declare that they have no competing interests."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Al-Mahayri",
      "given": "Zeina N.",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Khasawneh",
      "given": "Lubna Q.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Alqasrawi",
      "given": "Mais N.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Altoum",
      "given": "Sahar M.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Jamil",
      "given": "Gohar",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Badawi",
      "given": "Sally",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Hamza",
      "given": "Dana",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "George",
      "given": "Lizy",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "AlZaabi",
      "given": "Anwar",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Ouda",
      "given": "Husam",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Al-Maskari",
      "given": "Fatma",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "AlKaabi",
      "given": "Juma",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Patrinos",
      "given": "George P.",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0003-1306-6618",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Ali",
      "given": "Bassam R.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genomics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2022,
        9,
        25
      ]
    ],
    "date-time": "2022-09-25T05:02:36Z",
    "timestamp": 1664082156000
  },
  "deposited": {
    "date-parts": [
      [
        2022,
        9,
        25
      ]
    ],
    "date-time": "2022-09-25T05:03:28Z",
    "timestamp": 1664082208000
  },
  "funder": [
    {
      "DOI": "10.13039/100009122",
      "award": [
        "21M139",
        "21M139",
        "21M139",
        "21M139",
        "21M139",
        "21M139",
        "21M139"
      ],
      "doi-asserted-by": "publisher",
      "name": "Ministry of Higher Education and Scientific Research"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        3,
        14
      ]
    ],
    "date-time": "2024-03-14T18:09:31Z",
    "timestamp": 1710439771699
  },
  "is-referenced-by-count": 2,
  "issn-type": [
    {
      "type": "electronic",
      "value": "1479-7364"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2022,
        9,
        25
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-online": {
      "date-parts": [
        [
          2022,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2022,
            9,
            25
          ]
        ],
        "date-time": "2022-09-25T00:00:00Z",
        "timestamp": 1664064000000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2022,
            9,
            25
          ]
        ],
        "date-time": "2022-09-25T00:00:00Z",
        "timestamp": 1664064000000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-022-00417-9.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1186/s40246-022-00417-9/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-022-00417-9.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "prefix": "10.1186",
  "published": {
    "date-parts": [
      [
        2022,
        9,
        25
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2022,
        9,
        25
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1002/cpt.1664",
      "author": "MJ Chenoweth",
      "doi-asserted-by": "publisher",
      "first-page": "57",
      "journal-title": "Clin Pharmacol Ther",
      "key": "417_CR1",
      "unstructured": "Chenoweth MJ, Giacomini KM, Pirmohamed M, Hill SL, van Schaik RHN, Schwab M, et al. Global pharmacogenomics within precision medicine: challenges and opportunities. Clin Pharmacol Ther. 2020;107:57–61.",
      "volume": "107",
      "year": "2020"
    },
    {
      "DOI": "10.1007/s10557-021-07149-3",
      "author": "EF Magavern",
      "doi-asserted-by": "publisher",
      "first-page": "663",
      "journal-title": "Cardiovasc Drugs Ther",
      "key": "417_CR2",
      "unstructured": "Magavern EF, Kaski JC, Turner RM, Janmohamed A, Borry P, Pirmohamed M. The interface of therapeutics and genomics in cardiovascular medicine. Cardiovasc Drugs Ther. 2021;35:663–76.",
      "volume": "35",
      "year": "2021"
    },
    {
      "DOI": "10.1038/s41569-021-00549-w",
      "author": "JD Duarte",
      "doi-asserted-by": "publisher",
      "first-page": "649",
      "journal-title": "Nat Rev Cardiol",
      "key": "417_CR3",
      "unstructured": "Duarte JD, Cavallari LH. Pharmacogenetics to guide cardiovascular drug therapy. Nat Rev Cardiol. 2021;18:649–65.",
      "volume": "18",
      "year": "2021"
    },
    {
      "DOI": "10.2217/pgs.09.143",
      "author": "KJ Ellis",
      "doi-asserted-by": "publisher",
      "first-page": "1799",
      "journal-title": "Pharmacogenomics",
      "key": "417_CR4",
      "unstructured": "Ellis KJ, Stouffer GA, McLeod HL, Lee CR. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics. 2009;10:1799–817.",
      "volume": "10",
      "year": "2009"
    },
    {
      "DOI": "10.1161/CIRCINTERVENTIONS.119.007811",
      "author": "NL Pereira",
      "doi-asserted-by": "publisher",
      "journal-title": "Circ Cardiovasc Interv",
      "key": "417_CR5",
      "unstructured": "Pereira NL, Rihal CS, So D, Rosenberg Y, Lennon RJ, Mathew V, et al. Clopidogrel pharmacogenetics: state of the art review and the TAILOR-PCI Study. Circ Cardiovasc Interv. 2019;12: e007811.",
      "volume": "12",
      "year": "2019"
    },
    {
      "author": "MD Klein",
      "first-page": "647",
      "journal-title": "Am Heart Assoc",
      "key": "417_CR6",
      "unstructured": "Klein MD, Williams AK, Lee CR, Stouffer GA. Clinical utility of CYP2C19 genotyping to guide antiplatelet therapy in patients with an acute coronary syndrome or undergoing percutaneous coronary intervention arteriosclerosis thrombosis and vascular biology. Am Heart Assoc. 2019;39:647–52.",
      "volume": "39",
      "year": "2019"
    },
    {
      "DOI": "10.1016/j.tcm.2014.09.001",
      "author": "JA Johnson",
      "doi-asserted-by": "publisher",
      "first-page": "33",
      "journal-title": "Trends Cardiovasc Med",
      "key": "417_CR7",
      "unstructured": "Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015;25:33–41.",
      "volume": "25",
      "year": "2015"
    },
    {
      "DOI": "10.1007/s11096-022-01386-8",
      "author": "AM Fahmi",
      "doi-asserted-by": "publisher",
      "first-page": "599",
      "journal-title": "Int J Clin Pharm",
      "key": "417_CR8",
      "unstructured": "Fahmi AM, Elewa H, El Jilany I. Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review. Int J Clin Pharm. 2022;44:599–607.",
      "volume": "44",
      "year": "2022"
    },
    {
      "DOI": "10.1056/NEJMoa1311386",
      "author": "M Pirmohamed",
      "doi-asserted-by": "publisher",
      "first-page": "2294",
      "journal-title": "N Engl J Med",
      "key": "417_CR9",
      "unstructured": "Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369:2294–303.",
      "volume": "369",
      "year": "2013"
    },
    {
      "DOI": "10.3390/jcm9010022",
      "author": "RM Turner",
      "doi-asserted-by": "publisher",
      "first-page": "E22",
      "journal-title": "J Clin Med",
      "key": "417_CR10",
      "unstructured": "Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J Clin Med. 2019;9:E22.",
      "volume": "9",
      "year": "2019"
    },
    {
      "DOI": "10.3389/fgene.2020.575678",
      "doi-asserted-by": "publisher",
      "key": "417_CR11",
      "unstructured": "Kee PS, Chin PKL, Kennedy MA, Maggo SDS. Pharmacogenetics of statin-induced myotoxicity. Frontiers in genetics [Internet]. 2020 [cited 2022 Jun 30];11. Available from: https://www.frontiersin.org/article/https://doi.org/10.3389/fgene.2020.575678"
    },
    {
      "DOI": "10.1186/s13073-020-00821-7",
      "author": "AN Abou Tayoun",
      "doi-asserted-by": "publisher",
      "first-page": "116",
      "journal-title": "Genome Med",
      "key": "417_CR12",
      "unstructured": "Abou Tayoun AN, Rehm HL. Genetic variation in the Middle East-an opportunity to advance the human genetics field. Genome Med. 2020;12:116.",
      "volume": "12",
      "year": "2020"
    },
    {
      "DOI": "10.1038/s41598-020-78231-3",
      "doi-asserted-by": "crossref",
      "key": "417_CR13",
      "unstructured": "Al-Mahayri ZN, Patrinos GP, Wattanapokayakit S, Iemwimangsa N, Fukunaga K, Mushiroda T, et al. Variation in 100 relevant pharmacogenes among emiratis with insights from understudied populations. Scientific Reports. Nature Publishing Group; 2020;10:21310."
    },
    {
      "DOI": "10.1038/s41525-022-00281-5",
      "author": "PV Jithesh",
      "doi-asserted-by": "publisher",
      "first-page": "10",
      "journal-title": "NPJ Genom Med",
      "key": "417_CR14",
      "unstructured": "Jithesh PV, Abuhaliqa M, Syed N, Ahmed I, El Anbari M, Bastaki K, et al. A population study of clinically actionable genetic variation affecting drug response from the Middle East. NPJ Genom Med. 2022;7:10.",
      "volume": "7",
      "year": "2022"
    },
    {
      "DOI": "10.1007/s00439-021-02369-x",
      "doi-asserted-by": "publisher",
      "key": "417_CR15",
      "unstructured": "Tsermpini EE, Al-Mahayri ZN, Ali BR, Patrinos GP. Clinical implementation of drug metabolizing gene-based therapeutic interventions worldwide. Hum Genet [Internet]. 2021 [cited 2022 Feb 24]; Available from: https://doi.org/10.1007/s00439-021-02369-x"
    },
    {
      "DOI": "10.1186/s12875-020-01246-2",
      "doi-asserted-by": "crossref",
      "key": "417_CR16",
      "unstructured": "Al-Shamsi S. Performance of the Framingham coronary heart disease risk score for predicting 10-year cardiac risk in adult United Arab Emirates nationals without diabetes: a retrospective cohort study. BMC Fam Pract [Internet]. 2020 [cited 2020 Nov 1];21. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450595/"
    },
    {
      "key": "417_CR17",
      "unstructured": "Castor EDC. Castor electronic data capture [Internet]. 2019 [cited 2019 Aug 28]. Available from: https://castoredc.com"
    },
    {
      "key": "417_CR18",
      "unstructured": "gnomAD [Internet]. [cited 2020 Jun 18]. Available from: https://gnomad.broadinstitute.org/"
    },
    {
      "key": "417_CR19",
      "unstructured": "PharmVar [Internet]. [cited 2020 Oct 11]. Available from: https://www.pharmvar.org/"
    },
    {
      "DOI": "10.1002/cpt.2526",
      "doi-asserted-by": "crossref",
      "key": "417_CR20",
      "unstructured": "Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 Update. Clin Pharma and Therapeutics. 2022;cpt.2526."
    },
    {
      "DOI": "10.1002/cpt.668",
      "author": "JA Johnson",
      "doi-asserted-by": "publisher",
      "first-page": "397",
      "journal-title": "Clin Pharmacol Ther",
      "key": "417_CR21",
      "unstructured": "Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102:397–404.",
      "volume": "102",
      "year": "2017"
    },
    {
      "DOI": "10.1056/NEJMoa0809329",
      "doi-asserted-by": "crossref",
      "key": "417_CR22",
      "unstructured": "Estimation of the Warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360: 753–64."
    },
    {
      "DOI": "10.1002/phar.2089",
      "author": "A Shendre",
      "doi-asserted-by": "publisher",
      "first-page": "588",
      "journal-title": "Pharmacotherapy",
      "key": "417_CR23",
      "unstructured": "Shendre A, Parmar GM, Dillon C, Beasley TM, Limdi NA. Influence of age on warfarin dose, anticoagulation control, and risk of hemorrhage. Pharmacotherapy. 2018;38:588–96.",
      "volume": "38",
      "year": "2018"
    },
    {
      "DOI": "10.1002/cpt.2557",
      "author": "RM Cooper-DeHoff",
      "doi-asserted-by": "publisher",
      "first-page": "1007",
      "journal-title": "Clin Pharmacol Ther",
      "key": "417_CR24",
      "unstructured": "Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin Pharmacol Ther. 2022;111:1007–21.",
      "volume": "111",
      "year": "2022"
    },
    {
      "key": "417_CR25",
      "unstructured": "PharmVar [Internet]. [cited 2022 Jun 22]. Available from: https://www.pharmvar.org/gene/SLCO1B1"
    },
    {
      "DOI": "10.2217/pgs-2019-0134",
      "author": "D Primorac",
      "doi-asserted-by": "publisher",
      "first-page": "141",
      "journal-title": "Pharmacogenomics Future Med",
      "key": "417_CR26",
      "unstructured": "Primorac D, Bach-Rojecky L, Vađunec D, Juginović A, Žunić K, Matišić V, et al. Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of big data. Pharmacogenomics Future Med. 2020;21:141–56.",
      "volume": "21",
      "year": "2020"
    },
    {
      "DOI": "10.1155/2020/8703627",
      "author": "G Patti",
      "doi-asserted-by": "publisher",
      "first-page": "8703627",
      "journal-title": "Cardiovasc Ther",
      "key": "417_CR27",
      "unstructured": "Patti G, Micieli G, Cimminiello C, Bolognese L. The role of clopidogrel in 2020: a reappraisal. Cardiovasc Ther. 2020;2020:8703627.",
      "volume": "2020",
      "year": "2020"
    },
    {
      "DOI": "10.1056/NEJMoa1907096",
      "doi-asserted-by": "publisher",
      "key": "417_CR28",
      "unstructured": "Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van ’t Hof AWJ, van der Harst P, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621–31 https://doi.org/10.1056/NEJMoa1907096."
    },
    {
      "DOI": "10.3389/fphar.2020.582929",
      "doi-asserted-by": "publisher",
      "key": "417_CR29",
      "unstructured": "Zhang Y, Shi X-J, Peng W-X, Han J-L, Lin B-D, Zhang R, et al. Impact of implementing CYP2C19 genotype-guided antiplatelet therapy on P2Y12 inhibitor selection and clinical outcomes in acute coronary syndrome patients after percutaneous coronary intervention: A Real-World Study in China. Frontiers in pharmacology [Internet]. 2021 [cited 2022 Jun 19];11. Available from: https://www.frontiersin.org/article/https://doi.org/10.3389/fphar.2020.582929"
    },
    {
      "author": "ZN Al-Mahayri",
      "first-page": "47",
      "journal-title": "Pharmgenomics Pers Med",
      "key": "417_CR30",
      "unstructured": "Al-Mahayri ZN, Al Jaibeji HS, Saab Y, Soliman K, Al-Gazali L, Patrinos GP, et al. VKORC1 variants as significant predictors of warfarin dose in Emiratis. Pharmgenomics Pers Med. 2019;12:47–57.",
      "volume": "12",
      "year": "2019"
    },
    {
      "DOI": "10.3389/fphar.2022.866058",
      "doi-asserted-by": "publisher",
      "key": "417_CR31",
      "unstructured": "Asiimwe IG, Pirmohamed M. Ethnic diversity and warfarin pharmacogenomics. Frontiers Pharmacol [Internet]. 2022 [cited 2022 Jun 21];13. Available from: https://www.frontiersin.org/article/https://doi.org/10.3389/fphar.2022.866058"
    },
    {
      "DOI": "10.1001/jamanetworkopen.2020.27092",
      "author": "JL Vassy",
      "doi-asserted-by": "publisher",
      "journal-title": "JAMA Netw Open",
      "key": "417_CR32",
      "unstructured": "Vassy JL, Gaziano JM, Green RC, Ferguson RE, Advani S, Miller SJ, et al. Effect of pharmacogenetic testing for statin myopathy risk vs usual care on blood cholesterol: a randomized clinical trial. JAMA Netw Open. 2020;3: e2027092.",
      "volume": "3",
      "year": "2020"
    },
    {
      "DOI": "10.3390/jpm11111123",
      "author": "CA Brunette",
      "doi-asserted-by": "publisher",
      "first-page": "1123",
      "journal-title": "J Pers Med",
      "key": "417_CR33",
      "unstructured": "Brunette CA, Dong OM, Vassy JL, Danowski ME, Alexander N, Antwi AA, et al. A cost-consequence analysis of preemptive SLCO1B1 testing for statin myopathy risk compared to usual care. J Pers Med. 2021;11:1123.",
      "volume": "11",
      "year": "2021"
    },
    {
      "DOI": "10.1016/j.atherosclerosis.2021.05.016",
      "author": "JE Blais",
      "doi-asserted-by": "publisher",
      "first-page": "44",
      "journal-title": "Atherosclerosis",
      "key": "417_CR34",
      "unstructured": "Blais JE, Wei Y, Yap KKW, Alwafi H, Ma T-T, Brauer R, et al. Trends in lipid-modifying agent use in 83 countries. Atherosclerosis. 2021;328:44–51.",
      "volume": "328",
      "year": "2021"
    },
    {
      "DOI": "10.1016/j.amsu.2022.103304",
      "author": "W Abed",
      "doi-asserted-by": "publisher",
      "journal-title": "Ann Med Surg (Lond)",
      "key": "417_CR35",
      "unstructured": "Abed W, Abujbara M, Batieha A, Ajlouni K. Statin induced myopathy among patients attending the national center for diabetes, endocrinology, \u0026 genetics. Ann Med Surg (Lond). 2022;74: 103304.",
      "volume": "74",
      "year": "2022"
    },
    {
      "author": "B Tata",
      "first-page": "809",
      "journal-title": "Critical Rev Pharm",
      "key": "417_CR36",
      "unstructured": "Tata B, E, A Ambele M, S Pepper M,. Barriers to implementing clinical pharmacogenetics testing in Sub-Saharan Africa. Critical Rev Pharm. 2020;12:809.",
      "volume": "12",
      "year": "2020"
    },
    {
      "DOI": "10.3389/fgene.2021.740216",
      "doi-asserted-by": "publisher",
      "key": "417_CR37",
      "unstructured": "Jameson A, Fylan B, Bristow GC, Sagoo GS, Dalton C, Cardno A, et al. What are the barriers and enablers to the implementation of pharmacogenetic testing in mental health care settings? Frontiers in genetics [Internet]. 2021 [cited 2022 Jun 22];12. Available from: https://www.frontiersin.org/article/https://doi.org/10.3389/fgene.2021.740216"
    },
    {
      "DOI": "10.1111/bcp.13999",
      "author": "E Abou Diwan",
      "doi-asserted-by": "publisher",
      "first-page": "2076",
      "journal-title": "Br J Clin Pharmacol",
      "key": "417_CR38",
      "unstructured": "Abou Diwan E, Zeitoun RI, Abou Haidar L, Cascorbi I, Khoueiry ZN. Implementation and obstacles of pharmacogenetics in clinical practice: an international survey. Br J Clin Pharmacol. 2019;85:2076–88.",
      "volume": "85",
      "year": "2019"
    },
    {
      "DOI": "10.2217/pme.15.57",
      "author": "JA Luzum",
      "doi-asserted-by": "publisher",
      "first-page": "119",
      "journal-title": "Per Med",
      "key": "417_CR39",
      "unstructured": "Luzum JA, Luzum MJ. Physicians’ attitudes toward pharmacogenetic testing before and after pharmacogenetic education. Per Med. 2016;13:119–27.",
      "volume": "13",
      "year": "2016"
    }
  ],
  "reference-count": 39,
  "references-count": 39,
  "resource": {
    "primary": {
      "URL": "https://humgenomics.biomedcentral.com/articles/10.1186/s40246-022-00417-9"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genomics"
  ],
  "source": "Crossref",
  "title": [
    "Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "16"
}